Introduction
Next-generation sequencing (NGS) technologies allow massive-scale DNA sequencing at a low cost and are now driving biomedical research (Church, 2006; Mardis, 2008) . In a near future, large-scale projects in the life and medical sciences will depend on DNA sequencing as a readout, given that NGS platforms offer superior performance and specificity in many applications (Ansorge, 2009) . The purpose of this review is to summarize the current state-of-the-art in sequencing technologies from an end-user point-of-view. Particularly, our goal is to provide an overview of how biogerontologists can employ these technologies and the methods derived thereof to advance our knowledge of aging, longevity and age-related diseases. Lastly, we discuss some of the potential problems inherent to such high-throughput approaches, in particular at the levels of bioinformatics, statistics and data interpretation, and suggest possible solutions.
State-of-the-art in sequencing technology
The current crop of NGS platforms, also called secondgeneration sequencing technologies, was driven by the initial sequencing of genomes using traditional Sanger sequencing and its variants. Genome assemblies provided a reference to which the shorter sequence reads generated by NGS methods could be mapped back to, allowing for cheaper and faster sequencing (Fig. 1) . This has made second-generation platforms particularly adequate for studying humans and model organisms whose genomes had been sequenced already, as detailed below.
Generally, the principle behind second-generation platforms is to randomly fragment DNA or RNA into smaller pieces and construct a DNA or cDNA library-given their smaller sizes, microRNAs (miRNAs) can be used directly to make cDNA libraries. Libraries are sequenced at a high coverage and the sequenced reads are then mapped into the reference genome of the species (Fig. 1) . For genome resequencing, genetic variants can then be identified in the sample genome and for transcriptional profiling the number of reads mapping to each exon or mRNA can be quantified. Though mapping reads to a reference genome is much more common now, for an increasing number of projects, reads can also be assembled de novo. All these applications are further detailed below. Recent technological advances that allow faster and cheaper DNA sequencing are now driving biological and medical research. In this review, we provide an overview of state-of-the-art next-generation sequencing (NGS) platforms and their applications, including in genome sequencing and resequencing, transcriptional profiling (RNA-Seq) and high-throughput survey of DNA-protein interactions (ChIP-Seq) and of the epigenome. Particularly, we focus on how new methods made possible by NGS can help unravel the biological and genetic mechanisms of aging, longevity and age-related diseases. In the same way, however, NGS platforms open discovery not available before, they also give rise to new challenges, in particular in processing, analyzing and interpreting the data. Bioinformatics and software issues plus statistical difficulties in genome-wide studies are discussed, as well as the use of targeted sequencing to decrease costs and facilitate statistical analyses. Lastly, we discuss a number of methods to gather biological insights from massive amounts of data, such as functional enrichment, transcriptional regulation and network analyses. Although in the fast-moving field of NGS new platforms will soon take center stage, the approaches made possible by NGS will be at the basis of molecular biology, genetics and systems biology for years to come, making them instrumental for research on aging.
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